Thursday, March 26, 2020

09:00-11:00

SESSION 1 | OPENING SESSION

Chairs:

 Weidong Le, China | Sube Banerjee, UK 13.1.20; 11.2.20

09:00-09:15

09:15-09:30

Welcome remarks

Amos Korczyn, Israel and Anthony Schapira, UK

Welcome from the Association of British Neurologists (ABN)

Tom Warner, UK

09:30-10:00

Parkinson’s disease:  from mitochondria to lysosomes and on to therapy

Anthony Schapira, UK

10:00-10:30

Digital health technologies in clinical care and clinical trials

Jesse Cedarbaum, USA

10:30-11:00

Should cannabinoids be legally available to the public?

Peter Feldschreiber, UK

11:00-11:30

Coffee Break

11:30-13:00

SESSION 2 | THE MENTAL STATE

Chairs:

 George Chakhava, Georgia | Harry Sieratzki, UK

11:30-12:00

Neurostimulation and its potential to improve learning and cognition in health and disease

Roi Cohen Kadosh, UK

12:00-12:30

Functional neurological disorders

Stoyan Popkirov, Germany

12:30-13:00

Pathological impulsivity – a neurobehavioural phenomenon

Valerie Voon, UK

13:00-13:45

Lunch Break

13:45-15:15

SESSION 3 | NEUROIMMUNOLOGY

Chairs:

 Yuan-Han Yang, Taiwan | Ruta Mameniskiene, Lithuania

13:45-14:15

GAD antibodies spectrum disorder
Marinos Dalakas, USA

14:15-14:45

Multiple Sclerosis is one disease; why definitions matter to patients and how we treat them

Gavin Giovannoni, UK

15:15-16:45

SESSION 4 | DEMENTIA

Chairs:

Stavros Baloyannis, Greece | Robert Howard, UK 11.2.20 | Krylova Yanina, Russia 30.12.19; 9.2.20

14:45-15:15

Multimorbidity of the ageing brain

Johannes Attems, UK

15:15-15:45

Emerging neuropathological comorbidities in aging – LATE, ARTAG and CTE

Lea Grinberg, USA/Brazil

15:45-16:15

The two in one brain circulations

Vladimir Hachinski, Canada

16:15-16:45

Dementia and the arts

Sebastian Crutch, UK

16:45-17:00

Coffee Break

Chairs:

TBD | TBD

17:00-18:00

GWAS is likely to contribute significantly to Alzheimer’s disease (AD) patients care.

Capsule: Genome-wide association studies (GWAS) looking at genetic variants in different individuals may identify variants associated with disease. These cross-national investigations have been applied widely to AD, identifying dozens of “disease-specific” alterations. Is the huge and expensive investment likely to help in patient care?

17:00-17:10

Host: Peter Whitehouse, USA

17:10-17:25

Yes: Julie Williams, UK

17:25-17:40

No: Amos Korczyn, Israel

17:40-18:00

Discussions and rebuttals

18:00-18:30

Thomas Willis and the first decade of the brain

Alastair Compston, UK

18:30-19:00

Welcome to CONy 2020

19:00

Networking Reception